Imatinib Teva

Imatinib, the active ingredient in Imatinib Teva, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is indicated for several hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and helps achieve disease control. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates and prolongs survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by targeting c‑KIT signaling.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of the extremities, especially ankles. - Fatigue: persistent tiredness not relieved by rest. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Cardiac failure: signs of reduced heart function such as shortness of breath. - Pulmonary hypertension: elevated pressure in lung arteries. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Patients should be monitored for specific safety concerns before and during therapy. - Blood count monitoring: regular CBC to detect cytopenias. - Liver function assessment: periodic LFTs to identify hepatotoxicity. - Cardiac evaluation: baseline and periodic ECG for patients with cardiac history. - Hypersensitivity awareness: discontinue if severe rash or anaphylaxis occurs. - Pregnancy considerations: use only if potential benefit justifies potential risk. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce imatinib levels. - Antacids containing aluminum or magnesium: can decrease oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Loop diuretics: can exacerbate hypokalemia when combined. - QT‑prolonging agents: increase risk of cardiac arrhythmias, necessitating ECG surveillance.